Reliable diagnostics tests are necessary to identify individuals that have established an immune response against SARS-CoV-2 and will be basic to protect appropriately clinical staff and the general population in future outbreaks of Covid-19. Our laboratory has developed a test for the detection of antibodies against several viral proteins, expressed in bacteria collaboration with other groups of the CNB..
The serologic test has been validated in Madrid’s hospitals, where it is now being used in diagnostics, and will be produced and distributed by a Spanish company. National production is crucial since supply of tests has been a problem from the beginning of the pandemic. The test will also be used to assess the efficacy of new vaccines being developed in other laboratories at the CNB.
A second project involves detection of airborne viral particles disseminated by non-symptomatic individuals. Devices are being printed using 3D technology.